

ZIOPHARM ONCOLOGY INC
Form 8-K
June 06, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 6, 2011

ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)	001-33038 (Commission File Number)	84-1475672 (IRS Employer Identification No.)
---	---------------------------------------	--

1180 Avenue of the Americas 19th Floor New York, NY (Address of Principal Executive Offices)	10036 (Zip Code)
---	---------------------

(646) 214-0700
(Registrant's telephone number, including area code)

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

240.14d-2(b)).

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 8.01 Other Events

On June 6, 2011, ZIOPHARM Oncology, Inc. (the "Company") issued a press release disclosing clinical results from the Company's Phase Ib study of DC-RTS-IL-12, also referred to as ZIN-CTI-001, presented by Douglas J. Schwartzenuber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, at the 2011 Annual Meeting of the American Society of Clinical Oncology in Chicago, IL.

A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release dated June 6, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.

Date: June 6, 2011

By: /s/ Richard Bagley
Name: Richard Bagley
Title: President, Chief Operating Officer and
Chief Financial Officer

INDEX OF EXHIBITS

Exhibit No. Description

99.1 Press release dated June 6, 2011
